Medizone International, Inc. (MZEI: OTCBB) Get on Board Now — Or Regret it Later
Medizone International, Inc. (OTCBB: MZEI) From a commercial viewpoint, the higher the “kill rate” in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.
What we are witnessing here is not only AsepticSure moving beyond expectations in its hospital setting but broading the product scope and potential sales into bioterrorism applications.
AsepticSure™ BioTerrorism Applications
A field hardened version of AsepticSure™ is anticipated to be used in bioterrorism settings internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and has the potential to save lives. The potential of being able to eliminate 99.999992% (7.2 log kill) of an internationally accepted surrogate for Anthrax in 90 minutes will have national security implications.
This is precisely the time in the life of a biotech that you want to be on boaord.
January 20. 2010, Update
Unprecedented Kill Rates Foundation for Second Patent Application and Full Scale Hospital Mockup Underway
Medizone International announced unprecedented success in being able to predictably achieve 6 log (99.9999%) kill rates for the causative agents of Hospital Acquired Infections (HAIs) represented with AsepticSure™.
All samples tested during the third round of trials were either completely destroyed, that is no growth compared to the control samples, or so significantly reduced that the effect met the 6 log definition for sterilization.
These are the biggest culprits in hospital deaths for hospital acquired infections. MZEI is hitting the bullseye here. NO DOUBT ABOUT IT.
This is HUGE.
The actual results of this series of tests indicate reductions in pathogens, commonly associated with HAIs, can reliably be achieved by AsepticSure™ as follows:
- >6.5 log for C difficile
- >7 log for MRSA
- 7 log for E-coli
- 6.6 log for VRE
- 7 log for Pseudomonas aeruginous
- > 7 log for Bacillus subtilis
The sterilization of contaminated hospital spaces with a fully portable unit is now within reach without enormous expense, which will translate into greatly reduced suffering, thousands of lives saved and a dramatic cost benefit for the health care system globally.
Full Scale Hospital Mock Up Underway
Medizone’s research has now progressed to the full-scale mock up. By introducing the same combinations and protocols to room scale testing that produced >6 log with all HAI pathogens in the laboratory, our research team is confident the results produced should coincide with what has already been achieved in the most recent round of laboratory trials. Initial results from these scale-up trials can be expected in the near future.
DO NOT WAIT ON THIS. ONCE THE HOSPITAL MOCK UP RESULTS ARE ANNOUNCED THIS TRAIN MAY HAVE LEFT THE STATION.
YOU MAY NEVER FIND A BETTER TIME THAN NOW TO ABSOLUTELY GET ON BOARD.
Contact information:
Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com
Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970
Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
